A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Trial details
- Registry ID
- NCT05263999
- Drugs studied
- Itolizumab
TrialRedline tracks 2 clinical trials sponsored by Equillium: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)NCT05263999 | Itolizumab | Terminated | 2025-04-22Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataNCT05589610 | EQ101 | Completed | 2024-03-26Actual |
Names as written in the registry records.